BeiGene de­cides not to li­cense DKK1 drug, but keeps PD-1 com­bo tri­al in gas­tric can­cer

Back in ear­ly 2020, BeiGene struck a small, $132 mil­lion deal — com­plete with $3 mil­lion in cash and $5 mil­lion in eq­ui­ty in­vest­ment — to test out a new can­cer tar­get dubbed DKK1.

Three years lat­er, the drug­mak­er is tak­ing a pass on the op­tion to li­cense the as­so­ci­at­ed drug, DKN-01, leav­ing its col­lab­o­ra­tors at Leap Ther­a­peu­tics in search of a new part­ner.

When reached by End­points News, nei­ther BeiGene nor Leap spec­i­fied the rea­son for call­ing off the deal, which could have grant­ed BeiGene ex­clu­sive clin­i­cal and com­mer­cial rights for DKN-01 in cer­tain Asian mar­kets as well as Aus­tralia and New Zealand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER